EMG
UBX

Ellington Management Group’s Unity Biotechnology UBX Stock Holding History

Ellington Management Group’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,080
Closed -$103K – 803
2019
Q2 		$103K Buy
+1,080
New +$91.9K 0.02% 542

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ellington Management Group's UBX Position: Q3 2019 in Review

Ellington Management Group sold out of Unity Biotechnology (UBX) in Q3 2019, closing a stake of 1,080 shares — an estimated $103K sold.

Ellington Management Group first reported a position in UBX in Q2 2019 and held it in 1 quarter. The position peaked at $103K in Q2 2019. 63 funds tracked by Wall St. Rank hold UBX as of Q3 2019.

  • Ellington Management Group reported no remaining Unity Biotechnology position as of Q3 2019 after selling out during the quarter.
  • Ellington Management Group sold 1,080 Unity Biotechnology shares in Q3 2019, an estimated $103K.
  • Ellington Management Group first reported a position in Unity Biotechnology in Q2 2019 and held it in 1 quarter.
  • Ellington Management Group's Unity Biotechnology position peaked at $103K in Q2 2019.
  • 63 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2019.

Based on Ellington Management Group's 13F filing for Q3 2019, filed 14 Nov 2019.